ReviewJournal of molecular medicine (Berlin, Germany)2026
The role of the TIM-3 receptor in inflammatory bowel disease and autoimmunity: implications for TIM-3 and TCR crosstalk.
Review in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The T cell immunoglobulin and mucin-domain receptor 3 (TIM-3) is an immune checkpoint receptor with complex effects on T cell activation and tolerance. TIM-3 is expressed on the surface of T cells in close proximity to the T cell receptor (TCR), where it mainly acts co-inhibitory, despite lacking typical inhibitory immunoreceptor inhibition motifs, to regulate T cell activity or apoptosis. However, the underlying molecular mechanisms of its intracellular signal transduction remains incompletely understood. Central for the function of TIM-3 are conserved cytoplasmic tyrosine structures that require phosphorylation for downstream signaling. Previous findings suggest that several kinases linked to TCR signaling, including the Src family kinase Lck and the Tec kinase ITK can interact with TIM-3 and thereby regulate TCR signaling and fine-tune T cell activation and tolerance. The ligand-dependent phosphorylation of TIM-3 by ITK, together with the displacement of the adapter protein Bat3, illustrates how TIM-3 signaling modulates early TCR activation. In this review, we describe the interactions of TIM-3 and its various actors that can trigger TCR signaling. This review also aims to shed light on this complex network by providing an overview of the immune checkpoint receptor TIM-3 and its influence on various autoimmune diseases. The focus here is clearly on inflammatory bowel disease (IBD), and open questions about the TIM-3 network are outlined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.